Developing effective antibody therapeutics requires balancing innovation with efficiency—scientists must rapidly assess developability while minimizing bottlenecks in data access and analysis. Too often, researchers rely on fragmented tools or need to repeatedly request analyses from bioinformatics teams, leading to delays and inefficiencies. SignalsOne streamlines this process, enabling scientists to predict antibody liability sites and optimize candidates in real time—without waiting for pipeline results. This webinar will showcase Design-Make-Test- Decide as a framework for ADC discovery while emphasizing predictive antibody developability assessments, allowing you to do more with less.